IAS
ABCL icon

Insigneo Advisory Services’s AbCellera Biologics ABCL Stock Holding History

Insigneo Advisory Services’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,350
Closed -$35.4K – 746
2025
Q4 		$35.4K Buy
10,350
+20
+0.2% +$89 ﹤0.01% 697
2025
Q3 		$52K Buy
+10,330
New +$45.5K ﹤0.01% 686

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Insigneo Advisory Services's ABCL Position: Q1 2026 in Review

Insigneo Advisory Services sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 10,350 shares — an estimated $35.4K sold.

Insigneo Advisory Services first reported a position in ABCL in Q3 2025 and held it in 2 quarters. The position peaked at $52K in Q3 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Insigneo Advisory Services reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
  • Insigneo Advisory Services sold 10,350 AbCellera Biologics shares in Q1 2026, an estimated $35.4K.
  • Insigneo Advisory Services first reported a position in AbCellera Biologics in Q3 2025 and held it in 2 quarters.
  • Insigneo Advisory Services's AbCellera Biologics position peaked at $52K in Q3 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Insigneo Advisory Services's 13F filing for Q1 2026, filed 12 May 2026.